#breakthough

[buanasari]

Boost consumer revenues with moLotus advertising platform

Multiply your revenues & profits effortlessly via moLotus - only proven platform delivering breakthrough capabilities - subscriber monetization, transformation, scalability, lead generation, and beyond - https://www.molotus.com/

[rolainisblessed81]

Keep Believing In God

When it comes to trusting God the real battle is to KEEP standing in faith when your back is against the wall, and when it seems like hope is lost.But we must not give up in our faith if we are to receive what God has promised us. We must endure in faith.He is faithful. That’s what Hannah, Samuel the prophet’s mom had to do. She was unable to have children and she was being ridiculed for that.…

[weasel-of-stuff]

WHY DO I LOVE STANLEE SM KJAHKJSHKJHSKJAHKHHHDKJHX (i don't like like him i like him as a character :P)

creds to wooxd20 they make AMAZING art !!!!

Hiii :3

Urrrrrr

Can you fraw Stanley (ak the drugged guy from orin ayo)???????

Of course!!! I never drew it XD

[linguenuvolose]

Saturday 27.01.24 Zero degrees, sun, 1h40 min walk

[mermaidinthecity]

— I Won’t by Colbie Caillat

[reasonsforhope]

"A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Physician-scientist Linda-Gail Bekker, principal investigator for the South African part of the study, tells Nadine Dreyer what makes this breakthough so significant and what to expect next.

Tell us about the trial and what it set out to achieve

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs.

Lenacapavir (Len LA) is a fusion capside inhibitor. It interferes with the HIV capsid, a protein shell that protects HIV’s genetic material and enzymes needed for replication. It is administered just under the skin, once every six months.

The randomised controlled trial, sponsored by the drug developers Gilead Sciences, tested several things.

The first was whether a six-monthly injection of lenacapavir was safe and would provide better protection against HIV infection as PrEP for women between the ages of 16 and 25 years than Truvada F/TDF, a daily PrEP pill in wide use that has been available for more than a decade.

Secondly, the trial also tested whether Descovy F/TAF, a newer daily pill, was as effective as F/TDF...

The trial had three arms. Young women were randomly assigned to one of the arms in a 2:2:1 ratio (Len LA: F/TAF oral: F/TDF oral) in a double blinded fashion. This means neither the participants nor the researchers knew which treatment participants were receiving until the clinical trial was over.

In eastern and southern Africa, young women are the population who bear the brunt of new HIV infections. They also find a daily PrEP regimen challenging to maintain, for a number of social and structural reasons.

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency.

By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus...

What is the significance of these trials?

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV.

There were 1.3 million new HIV infections globally in the past year. Although that’s fewer than the 2 million infections seen in 2010, it is clear that at this rate we are not going to meet the HIV new infection target that UNAIDS set for 2025 (fewer than 500,000 globally) or potentially even the goal to end Aids by 2030...

For young people, the daily decision to take a pill or use a condom or take a pill at the time of sexual intercourse can be very challenging.

HIV scientists and activists hope that young people may find that having to make this “prevention decision” only twice a year may reduce unpredictability and barriers.

For a young woman who struggles to get to an appointment at a clinic in a town or who can’t keep pills without facing stigma or violence, an injection just twice a year is the option that could keep her free of HIV.

What happens now?

The plan is that the Purpose 1 trial will go on but now in an “open label” phase. This means that study participants will be “unblinded”: they will be told whether they have been in the “injectable” or oral TDF or oral TAF groups.

They will be offered the choice of PrEP they would prefer as the trial continues.

A sister trial is also under way: Purpose 2 is being conducted in a number of regions including some sites in Africa among cisgender men, and transgender and nonbinary people who have sex with men.

It’s important to conduct trials among different groups because we have seen differences in effectiveness. Whether the sex is anal or vaginal is important and may have an impact on effectiveness.

How long until the drug is rolled out?

We have read in a Gilead Sciences press statement that within the next couple of months [from July 2024] the company will submit the dossier with all the results to a number of country regulators, particularly the Ugandan and South African regulators.

The World Health Organization will also review the data and may issue recommendations.

We hope then that this new drug will be adopted into WHO and country guidelines.

We also hope we may begin to see the drug being tested in more studies to understand better how to incorporate it into real world settings.

Price is a critical factor to ensure access and distribution in the public sector where it is badly needed.

Gilead Sciences has said it will offer licences to companies that make generic drugs, which is another critical way to get prices down.

In an ideal world, governments will be able to purchase this affordably and it will be offered to all who want it and need protection against HIV."

-via The Conversation, July 3, 2024

[genderqueerdykes]

i just wanted to say that i love you if you want or you've gotten bottom surgery. people are so cruel about trans, intersex, gnc and other folks who want to get bottom surgery for one reason or another, whether it's to ease dysphoria or simply because they want to, people love to rip into that person and tell them that bottom surgery will make them undesirable and will be disgusting.

this literally just isn't true- the results of your bottom surgery are not guaranteed to be botched or horrific to behold. we have been practicing these surgeries for 100 years of recorded history and the results only improve over time as we learn new techniques and breakthoughs in technology help us improve even further. bottom surgery isn't new, it's something that's been practiced for a long time. many of the advances in the tech have come from cisgender people who need bottom surgery as well- trans people are not the only people who end up needing surgeries to modify their genitalia.

someone who wants bottom surgery isn't gross. there's nothing gross about it. reducing someone to their genitals yet again is a dead ringer that you are transphobic and intersexist. someone who got bottom surgery doesn't deserve to be reduced to their genitals yet again- they're a person with genitals. a person first. and so many people are willing to leave trans folks who have gotten bottom surgery out of trans positivity posts or act like they just straight up don't exist

so here's to every person who has gotten a phalloplasty, metoidioplasty, and/or a vaginoplasty. i'm proud of you for doing the right thing for you and your body no matter what people say. you're not gross. there's nothing wrong with your genitals. people should not be obsessing over your genitals, they're your business, and they do not define you as a person. you deserve to be able to modify your body in ways that make you feel at home in it, no matter how much that disgusts a stranger who means nothing to you.

[cinamun]

Indira's breakthough 5 page spread in Del Sol Magazine hit shelves at midnight, however, courtesy copies were hand delivered about an hour before to her parents (of course).

Now that stores have opened, you can have a copy too!

Download & Details under the cut

What you get:

Readable magazine in 2 swatches (Spa Day required)

Decor magazine in 2 swatches

Magazine Rack recolor in 1 swatch

Custom Thumbnails

Search for "magazine" and you'll find it

Meshes by @surely-sims (Showroom Living), @wtrshpdwn included (thank you!)

Grab the wall rack mesh here <-

DOWNLOAD <- (Alt)

Enjoy!

[pansyfemme]

i think any sort of extended lifetime would really change your perspective of gender as it is, and more so than just simply coming out as trans. if you were immortal or just had a much longer than human lifespan you might have time to transition and detransition back and forth every so often. you’d live to see new social and medical transition breakthoughs, it could be great. but if you realized you were trans in the timeloop? well, as the days piled up you would have a lot of time to think about it but every step you took- coming out, buying clothes, or even if you somehow managed to obtain hrt or surgery within a single day- would be reversed, which would be possibly the most fucked up thing ever but may eventually lead to an additude towards gender transition we’ve never seen the likes of before

[infernalroses]

My submission for the Boggio Skin Contest! Cocoagraft! A breakthough in engineering, a Biograft who can fight AND create a nice, steaming cup of hot chocolate! Sadly, Subspace seems to have gotten a bit too mad at this certain Biograft after issues with giving the mugs of hot chocolate, but don't mind that! --- plus an extra

[mrrubbersuitman]

Regulary $35.00, on sale until 12/2 for $26.25

[hungnitan]

HSR x Fate UBW collab story review

Before I started reviewing, I had mixed feelings since they annouce the collab like I love Fate series and know most of series while at same time they only brought smol character from UBW. Then they announce the collab use Penacony settings plus the character only Saber Archer and npc Lancer so yeah real mix feels.

But the one I'm sure after read this collab story is that this stories couldn't be write if they don't know Fate series as whole. I notice smol details like holy grail war details mentioned and their idea of the reason Oti annouce Penacony holy grail war.

Conclusion : 5/10

Had a good start with FSN nostalgic scenes but too bad Assassin + Caster similar noble phantasm practically destroy most of stories especially Assassin's. Half stories spinned around Assassin + Skott useless yapping + silent story, if not Churin and Archer duo comedy there I could dying out of boreness (lol). It could done better if Hoyo using same Fate premise for making Assassin (Kojiro like) to work together with Caster or just cut the Assassin scenes part (lol)

Other than that big problem, some small problems like TB Saber interaction feels dry, even more with Boothill Lancer. Maybe Hoyo try to promote Archer more than Saber (lol).

I still think this collab story pretty good, but the one I wonder is why it include as permanent story ? Permanent story means it had any connection to TB main story, means there are something more about this collab story...

Mentionable scene :

Guinafen smol mention, if anyone remember HSR Guinafen backstory pretty much same as her Fate counterpart since she mentioned same Knight of Round members. It's just a bit twist there and there (lol) so yeah I'm sure HSR are planning to collab with Fate even before HSR release

If so why Britain use Aedes Elysiae settings ? Well my smol speculation is just Saber LC background looks similar to Aedes Elysiae (lol)

The real scariest part about what if TB didn't aboard into Astral Express. Nanoka in koma state, Danheng comeback to Luofu and Welt to earth, leaving only Himeko and Pom Pom means AE won't come to Amphoreus...

Tbh I don't wanna think about Danheng parts, maybe he went back into jail again...

Their master servant relationships is the most I savor for this event story ! They're so match like glue and stick (lol).

Master who merits the most in this Penacony Holy grail war I guess. It's pretty funny too they spend the time only by chatting together.

PS : then again I pretty much enjoy this collab especially gameplay gimmick. I pretty like using Archer/Assassin/Rider combination + bit Lancer Caster Rider pieces but Berserker is the best !

Yup I breakthough all challenge by using Berserker pieces only ! Mydeimos is the best for this pieces. Just one more but I'm sure same deck pretty much finish the game~

And Saber pieces suck if not using Saber. To think I feel so despair using Saber, am I Siegfried main (lol)

[zephamello]

breakthrough opinions means you know who's coming up...mack hans time

Holy Mackerel Hans, Mack and Cheese Hans. We love him. Anyone who doesn't love him I'm genuinely interested in knowing why.

I feel bad for him :( His decisions he made for himself and also his lore, man Breakthrough overall is just depressing alskjdnldkfb I really want to just give him a hug, and a comfy blanket and a sweet little treat, bro has been through it he DESERVES a hug and a comfy blanket and a sweet little treat.

His sound is depressing too :( It just gives that vibe of "I'm sad bc of choices I've made and I'm not a big fan of me." Again though, it is perfect for Breakthough.

Him and Tab are lowkey a wholesome couple and I wish they didn't have to have that ending ;;

(You are never gonna guess whose design for him and the ship art of him and Tab I am obsessed with. I'll give you a hint, it rhymes with box guy blazey.)

mack and cheese

[starleo]

I just made a breakthough with finding out what the end of the trailer for Pokemon Legends: Z-A means.

Promotion / Prohibtion Match means a speical match used to advertise the premiere of certain products or film releases. Could this mean that Leon got yeeted to the future of Kalos?

[warningsine]

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Physician-scientist Linda-Gail Bekker, principal investigator for the South African part of the study, tells Nadine Dreyer what makes this breakthough so significant and what to expect next.

Tell us about the trial and what it set out to achieve

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs.

Lenacapavir (Len LA) is a fusion capside inhibitor. It interferes with the HIV capsid, a protein shell that protects HIV’s genetic material and enzymes needed for replication. It is administered just under the skin, once every six months.

The randomised controlled trial, sponsored by the drug developers Gilead Sciences, tested several things.

The first was whether a six-monthly injection of lenacapavir was safe and would provide better protection against HIV infection as PrEP for women between the ages of 16 and 25 years than Truvada F/TDF, a daily PrEP pill in wide use that has been available for more than a decade.

Secondly, the trial also tested whether Descovy F/TAF, a newer daily pill, was as effective as F/TDF. The newer F/TAF has superior pharmacokinetic properties to F/TDF. Pharmacokinetic refers to the movement of a drug into, through, and out of the body. F/TAF is a smaller pill and is in use among men and transgender women in high-income countries.

The trial had three arms. Young women were randomly assigned to one of the arms in a 2:2:1 ratio (Len LA: F/TAF oral: F/TDF oral) in a double blinded fashion. This means neither the participants nor the researchers knew which treatment participants were receiving until the clinical trial was over.

In eastern and southern Africa, young women are the population who bear the brunt of new HIV infections. They also find a daily PrEP regimen challenging to maintain, for a number of social and structural reasons.

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency.

By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus.

The results at a recent independent data safety monitoring board review led to the recommendation that the trial’s “blinded” phase should be stopped and all participants should be offered a choice of PrEP.

This board is an independent committee of experts who are put in place at the start of a clinical trial. They see the unblinded data at stipulated times during the trial to monitor progress and safety. They ensure that a trial does not continue if there is harm or a clear benefit in one arm over others.

What is the significance of these trials?

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV.

There were 1.3 million new HIV infections globally in the past year. Although that’s fewer than the 2 million infections seen in 2010, it is clear that at this rate we are not going to meet the HIV new infection target that UNAIDS set for 2025 (fewer than 500,000 globally) or potentially even the goal to end Aids by 2030.

PrEP is not the only prevention tool.

PrEP should be provided alongside HIV self-testing, access to condoms, screening and treatment for sexually transmitted infections and access to contraception for women of childbearing potential.

In addition, young men should be offered medical male circumcision for health reasons.

But despite these options, we haven’t quite got to the point where we have been able to stop new infections, particularly among young people.

For young people, the daily decision to take a pill or use a condom or take a pill at the time of sexual intercourse can be very challenging.

HIV scientists and activists hope that young people may find that having to make this “prevention decision” only twice a year may reduce unpredictability and barriers.

For a young woman who struggles to get to an appointment at a clinic in a town or who can’t keep pills without facing stigma or violence, an injection just twice a year is the option that could keep her free of HIV.

What happens now?

The plan is that the Purpose 1 trial will go on but now in an “open label” phase. This means that study participants will be “unblinded”: they will be told whether they have been in the “injectable” or oral TDF or oral TAF groups.

They will be offered the choice of PrEP they would prefer as the trial continues.

A sister trial is also under way: Purpose 2 is being conducted in a number of regions including some sites in Africa among cisgender men, and transgender and nonbinary people who have sex with men.

It’s important to conduct trials among different groups because we have seen differences in effectiveness. Whether the sex is anal or vaginal is important and may have an impact on effectiveness.

How long until the drug is rolled out?

We have read in a Gilead Sciences press statement that within the next couple of months the company will submit the dossier with all the results to a number of country regulators, particularly the Ugandan and South African regulators.

The World Health Organization will also review the data and may issue recommendations.

We hope then that this new drug will be adopted into WHO and country guidelines.

We also hope we may begin to see the drug being tested in more studies to understand better how to incorporate it into real world settings.

Price is a critical factor to ensure access and distribution in the public sector where it is badly needed.

Gilead Sciences has said it will offer licences to companies that make generic drugs, which is another critical way to get prices down.

In an ideal world, governments will be able to purchase this affordably and it will be offered to all who want it and need protection against HIV.

[thewickerking]

"Yeah so you were right about lizard brain. The spirit psychosis is about to happen" "I am the sun everything revolves around me" guys... must we..... "BREAKTHOUGH AGAIINNNNN" what are yall taking about.. lizard brain and spiritual psychosis is a breakthrough??????? what 😭